Antisera andM.Abs. Rat anti-mouse M.Abs. directed aganst Thy-l.2 (30-H12 hybridoma), Lyt-1 (53-7.3 hybridoma cell line), Lyt-2 (53-6.7 hybridoma), and Lyt-3.2 (53-5.8 hybridoma) were described previously (3, 4) . Fluorescein isothiocyanate (FITC) goat anti-mouse p heavy chain serum was obtained from Meloy Laboratories , Inc., Springfield, Va. FITC mouse (SJL) anti-rat Ig serum was prepared as described elsewhere. 1
Immunofluorescence and FCM. Immunofluorescence was performed as described in detail elsewhere (7) . Fluorescence was measured by FCM analysis using a FACS III (B-D FACS Systems, Mountain View, Calif.) (7, 8) .
Toipsin Stripping of Surface Antigens. 10 million cells were suspended in 30 ml RPMI-1640 containing 10 mg/ml trypsin (type IX, from porcine pancreas, Sigma Chemical Co., St. Louis, Mo.). After incubation for 1 h at 37°C, the digestion was halted by the addition of 3 ml heatinactivated fetal calf serum (HIFCS). The cells were washed twice in medium with 20% HIFCS and placed in medium with 20% HIFCS, 10 -4 2-Mercaptoethanol, 2 mM glutamine, 100/x/ml penicillin, and 100 pg/ml streptomycin. Cells were examined by FCM immediately after enzyme treatment and again after overnight culture. Earlier reports have suggested that Lyt-1 is trypsin resistant (3). However, by using high concentration of enzyme (>5 mg/ml), it was possible to remove completely surface Lyt-1 without loss of cell viability.
Biosynthetic Labeling, Immunoprecipitation, and Gel Electrophoresis. 200 million WEHI-55 cells were labeled with ~S-methionine for 30 rain in methionine-deficient RPMI-1640 containing I0% dialyzed HIFCS and 1 mCi aSS-methionine (Amersham Corp., Arlington Heights, Ill.). The cells were chased in 200 ml medium for 5 h, then extracted with 4 ml lysis buffer (0.5% Nonidet-P40, Particle Data, Inc., Elmhurst, Ill.; 50 mM Tris; 150 mM NaCI; 0.02% NaNs; 5 mM EDTA; 50 mM phenylmethylsulfonyi fluoride; 0.2 trypsin inhibiting units per ml Aprotinin (Sigma Chemical Co.), 1 pg/ml pepstatin A (Sigma Chemical Co.), 50 mM iodoacetamide, pH 8.0) for 30 min at 40C. Nuclei were removed by centrifugation at 5,000 g for 20 rain. Proteins, immunopreeipitated with rabbit anti-mouse Ig, anti-Lyt-1 M.Ab., and fixed Staphylococcus aureus Cowan I strain (9), were run on 10% sodium dodeeyl sulfate (SDS)-polyaerylamide gels as previously described (10) . Gels were treated with Enhance (New England Nuclear, Boston, Mass.) for fluorography and autoradiographs were made with Kodak X-Omat R film (Eastman Kodak Co., Rochester, N. Y.) at -70°C. Molecular weight standards (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) were run in a parallel gel lane and were visualized by staining with Coomassie brilliant blue (Bio-Rad Laboratories, Richmond, Calif.).
Results

Analysis of B Cell Lymphomas by FCM.
Recently, we examined a series of B cell lymphomas for the presence of T cell differentiation antigens. The most striking finding was that three surface Ig +, Ia + B lymphomas unequivocally expressed the Lyt-1 antigen, whereas none expressed the Thy-l.2 or Lyt-2 determinants (Table I) . The CH5 and WEHI-259 splenic tumors clearly demonstrate the presence of surface IgM and Lyt-1, but not the Thy-l.2, Lyt-2, or Lyt-3.2 antigens. CH5 was held in culture for 5 d, and was still found to express IgM and Lyt-1. Trace amounts of Lyt-1 were also detected on CH4, CH6, and WEHI-5. The WEHI-55 B lymphoma, which has been maintained in continuous cell culture over the past 12 too, also expresses both surface IgM/IgD and the Lyt-1 antigen, but not Thy-l.2, Lyt-2, or Lyt-3.2 ( Fig. 1) .
T~ypsin Stripping and Regeneration of Lyt-1 in Culture. Because WEHI-259 and CH5
have not been established in permanent cell culture as yet, it is possible that the Lyt-1 antigen was passively acquired in vivo. Hence, the splenic tumor cells were treated with trypsin, analyzed for removal of Lyt-1, and placed in tissue culture. After overnight culture, the trypsin-stripped cells, as well as untreated CH5 and WEHI-259 cells, were again examined for presence of Lyt-l. As shown in Fig. 2 , enzymatic treatment with trypsin successfully removed the Lyt-1 antigen. However, within 18 h, >90% of the trypsin-stripped cells again expressed Lyt-1 in the same quantity as the untreated control cells.
Immunoprecipitation of Immunoglobulin and Lyt-1 from WEHI-55.
Lyt-1 has been immunoprecipitated from normal thymocytes after surface-labeling with 12sI and lactoperoxidase, and has been shown to be a glycoprotein of ~67,000-70,000 mot wt (3, 11) . In addition, a higher molecular weight form of Lyt noprecipitation after surface-labeling of carbohydrates with [3H]borohydride (11) . We used biosynthetic labeling of WEHI-55 cells with aSS-methionine, followed by immunoprecipitation with anti-Lyt-1, to see if the molecular form of Lyt-1 on this B lymphoma is similar to Lyt-1 from T cells. Fig. 3 shows the anti-Ig, anti-Lyt-1, and control immunoprecipitations from WEHI-55. The anti-Ig serum specifically immunoprecipitated a single light chain and two heavy chains that correspond in size to 8 chain and ~ chain (75,000 and 85,000 mol wt, respectively). Thus, the Lyt-1 glyeoprotein expressed on WEHI-55 shows a similar structure to the Lyt-1 glycoprotein on thymocytes.
Discussion
Previous studies have implied that Lyt-I is only present on thymus-derived lymphocytes and that this molecule is associated with certain specific functional subsets of T cells (1, 2) . However, using FCM analysis and M.Abs., we have conclusively demonstrated that certain B lymphomas may indeed express the Lyt-1 antigen. Of the 11 B lymphomas examined, three tumors expressed high levels of the Lyt-1 antigen. Furthermore, three other tumors gave weak but detectable reactions with the anti-Lyt-1 M.Ab. Although these tumors expressed this presumably "T cell specific" antigen, they were otherwise typical B lymphomas. All expressed surface Ig, Ia antigens, and Fc receptors. None expressed other T cell differentiation antigens such as Thy-1, Lyt-2, Lyt-3, or the T30 antigen (6) . 1 Because such a large percentage of these surface Ig + B lymphomas was found to express Lyt-1, it seems that expression of this antigen is probably not due to random Immunoprecipitates were electrophoresed on 10% SDS-polyacrylamide gels under reducing conditions.
gene derepression in a transformed cell line. One possibility is that the small subset of B lymphocytes, which presumably express Lyt-1, is extremely susceptible to oncogenic transformation. At present, there is no evidence to support this hypothesis. It should be noted that with respect to other surface markers, these Lyt-1 ÷ tumors are quite heterogeneous (6) .1 Moreover, analysis of the expression of differentiation antigens on these tumors does not support the idea that they are from a homogeneous subpopulation of B cells. Another possibility is that leukemogenesis selectively includes expression of Lyt-1 on certain B lymphomas. Along these lines, it also is conceivable that normal B cells express Lyt-1 in undetectable amounts. However, the rapid proliferation and increase in cell size associated with transformation may increase expression of the existing antigen, therefore allowing detection.
O f particular relevance are the recent reports that the human Leu-1 antigen is expressed on most human B chronic lymphocytic leukemias, but not on normal human B lymphocytes (9, 12) . Immunochemical and functional studies have demonstrated that human Leu-1 is probably the homologue of the mouse Lyt-1 antigen (9). Thus, the finding that murine Lyt-1 and its putative human counterpart Leu-1 are usually expressed on normal T cells, but are also present on B cell malignancies, implies a common mechanism of gene regulation (9) .
A final point is that both the Leu-1 and Lyt-1 molecules on T cells have molecular weights of ---67,000-70,000 (9, 12) . Immunoprecipitation analysis of the Lyt-1 antigen on WEHI-55 has shown a single diffuse band of protein with approximately the same average molecular weight. This suggests that the B lymphoma Lyt-1 protein is similar to the T cell antigen, perhaps with glycosylation differences. Bases on these data, a more extensive examination of normal B lymphocytes is needed to resolve the apparent discrepancy of Lyt-1 expression of B lymphomas vs. normal lymphoid cells.
S u m m a r y Although the Lyt-1 antigen has previously been considered a T cell-specific marker, recent evidence suggests that a population of T h y -l -, Lyt-l* cells exists in normal lymphoid tissues. In this study, we have observed that the WEHI-55, WEHI-259, and CH5 B cell lymphomas express high levels of the Lyt-1 antigen, as detected by monoclonal antibodies using the fluorescence-activated cell sorter. Three other B cell lymphomas of the 11 examined also gave weak but detectable reactions with the antiLyt-1 monoclonal antibody. Except for the expression of the Lyt-1 antigen, these lymphomas are typical of cells in the B cell lineage with respect to surface phenotype. The Lyt-1 glycoprotein immunoprecipitated from metabolically labeled WEHI-55 cells is similar in structure to the Lyt-1 glycoprotein on thymocytes. These findings are similar to recent reports that B-type human lymphocytic leukemia cells express the putative human homologue of Lyt-1, the Leu-1 antigen.
